BETA


2013/0243(COD) Second European and Developing Countries Clinical Trials Partnership Programme (EDCTP2): participation of the Union

Progress: Procedure completed

RoleCommitteeRapporteurShadows
Lead ITRE FORD Vicky (icon: ECR ECR) CARVALHO Maria Da Graça (icon: PPE PPE), RIERA MADURELL Teresa (icon: S&D S&D), HALL Fiona (icon: ALDE ALDE), RIVASI Michèle (icon: Verts/ALE Verts/ALE)
Committee Opinion DEVE PONGA Maurice (icon: PPE PPE)
Committee Opinion BUDG
Committee Opinion ENVI
Lead committee dossier:
Legal Basis:
TFEU 185, TFEU 188-p2

Events

2014/07/09
   EC - Commission response to text adopted in plenary
Documents
2014/06/07
   Final act published in Official Journal
Details

PURPOSE: to contribute to the reduction of the social and economic burden of poverty-related diseases in developing countries, and in particular in sub-Saharan Africa.

LEGISLATIVE ACT: Decision No 556/2014/EU of the European Parliament and of the Council on the participation of the Union in a second European and Developing Countries Clinical Trials Partnership Programme (EDCTP2) jointly undertaken by several Member States

CONTENT: this Decision is part of a package of four legal acts for a new generation of public -private partnerships that will allow large-scale, long-term innovation projects to be carried out under the umbrella of Horizon 2020, the EU's research and innovation framework programme.

Three other public-public partnerships will be further developed on research programmes jointly undertaken by Member States with the participation of the Union in the areas of:

· a second research and development programme aimed at supporting research and development performing small and medium-sized enterprises (‘Eurostars-2’ );

· a programme on research and development on active and assisted living ( AAL programme );

· a European research and innovation programme on metrology ( EMPIR ) ;

Objective: the Decision establishes the rules and conditions for Union participation in the second European and Developing Countries Clinical Trials Partnership Programme (the ‘EDCTP2 Programme’), jointly undertaken by Austria, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden, Switzerland and the United Kingdom.

Any Member State and any other country associated to Horizon 2020 may apply to join the programme, provided it fulfils the conditions regarding financial contribution.

Programme objectives : EDCTP1 (2003-2012) produced major achievements, and developed eight improved medical treatments, in particular for newborns, children and pregnant or breastfeeding women suffering from HIV/AIDS or malaria.

In extending the first programme, EDCTP-II will contribute to the reduction of the social and economic burden of poverty-related diseases in developing countries, and in particular in sub-Saharan Africa, by accelerating the clinical development of effective, safe, accessible, suitable and affordable medical interventions for poverty-related diseases in partnership with sub-Saharan countries.

The specific objectives are, inter alia:

· an increased number of new or improved medical interventions for HIV/AIDS, tuberculosis, malaria and other poverty-related diseases , including neglected ones, and by the end of the programme to have delivered at least one new medical intervention; to have issued approximately 30 guidelines and approximately 20 candidate medical interventions;

· strengthened cooperation with sub-Saharan African countries, in particular on building their capacity for conducting clinical trials in compliance with fundamental ethical principles and relevant national, Union and international legislation;

· better coordination, alignment and, where appropriate, integration of relevant national programmes to increase the cost-effectiveness of European public investments;

· extended international cooperation with other public and private partners to ensure that the impact of all research is maximised and that synergies can be taken into consideration and achieve leveraging of resources and investments.

Union financial contribution: the Union’s financial contribution, including EFTA appropriations, to the EDCTP2 Programme shall be up to EUR 683 000 000 to equal the contributions of Participating States.

This contribution shall be paid from the appropriations allocated to the relevant parts of the Specific Programme implementing Horizon 2020 , and in particular from the appropriations under the specific objective ‘Health, demographic change and wellbeing’.

Implementation: the Participating States have agreed on the implementation structure for EDCTP2 Programme and have set up the EDCTP2-Implementation Structure (‘EDCTP2-IS’). The EDCTP2-IS should be the recipient of the Union’s financial contribution and should ensure the efficient implementation of the EDCTP2 Programme.

Calls for proposals should be launched at the latest by 31 December 2020. In duly justified cases they may be launched by 31 December 2021. Calls for proposals should also be published on the single portal for participants as well as through other Horizon 2020 electronic means of dissemination managed by the Commission.

In order to protect the Union’s financial interests , the Commission should have the right to reduce, suspend or terminate the Union’s financial contribution if the programme is implemented inadequately.

Evaluation : by 30 June 2017, the Commission shall carry out an interim evaluation of EDCTP-II with the help of independent experts. It shall send that report to the European Parliament and to the Council by 31 December 2017. The result of the interim evaluation of the programme shall be taken into account in the interim evaluation of Horizon 2020.

ENTRY INTO FORCE: 27.06.2014.

2014/05/15
   CSL - Draft final act
Documents
2014/05/15
   CSL - Final act signed
2014/05/15
   EP - End of procedure in Parliament
2014/05/06
   EP/CSL - Act adopted by Council after Parliament's 1st reading
2014/05/06
   CSL - Council Meeting
2014/04/15
   EP - Results of vote in Parliament
2014/04/15
   EP - Decision by Parliament, 1st reading/single reading
Details

The European Parliament adopted by 646 votes to 13, with 12 abstentions, a legislative resolution on the proposal for a decision of the European Parliament and of the Council on the participation of the Union in a second European and Developing Countries Clinical Trials Partnership Programme (EDCTP2) jointly undertaken by several Member States.

Parliament adopted its position at first reading under the ordinary legislative procedure. The amendments adopted in plenary were the result of a compromise between Parliament and Council. They amend the Commission’s proposal as follows:

Union financial contribution : as stated in the Commission proposal, this would be EUR 683 million, to equal the contributions of Participating States.

It will be paid from the appropriations in the general budget of the Union allocated to the relevant parts of the Specific Programme implementing Horizon 2020 , and in particular from the appropriations under the specific objective " Health, demographic change and wellbeing ".

To take account of the duration of the Horizon 2020 Programme, all calls for proposals should be launched by 31 December 2020 .

Scope: in the Communication of 27 February 2013 entitled "A decent life for all: ending poverty and giving the world a sustainable future", the Commission reaffirmed its commitment to doing its utmost to help achieve the MDG by 2015, and pointed out that EU-funded research under EDCTP1 had contributed to achieving the MDG.

Parliament and Council agreed to amend and extend the current scope of EDCTP1 by :

· strengthening the capabilities in developing countries for the sound conduct and management of clinical trials, in particular the role and development of ethical review committees and the corresponding regulatory environment, the coordination, collaboration and, where appropriate, improving integration of European national programmes ;

· extending collaboration with other major public and private partners, including the pharmaceutical industry, and public-private partnerships such as the Product Development Partnerships ("PDPs"), civil society, non-governmental organisations and foundations;

· ensuring clear and transparent rules of governance.

EDCTP2 activities : activities may include activities undertaken by public or private not-for-profit research organisations, and new activities, including calls for proposals managed by the EDCTP2-IS.

The programme should contribute to the reduction of the social and economic burden of poverty-related diseases in developing countries, and in particular in sub-Saharan Africa, by accelerating the clinical development of effective, safe, accessible, suitable and affordable medical interventions for such diseases, (such as drugs, microbicides or vaccines, including their delivery modality, follow up of treatment and prevention in the affected population as well as medical diagnostics to detect and monitor disease/health evolution.)

The specific objectives will be, inter alia :

· an increased number of new or improved medical interventions for HIV/AIDS, tuberculosis, malaria and other poverty-related diseases, including neglected ones , and by the end of the programme to have delivered at least one new medical intervention, issued approximately 30 guidelines, and have progressed the clinical development of approximately 20 candidate medical interventions;

· establish the research priorities in an objective-orientated manner in order to accelerate results and contribute to the control and eradication of poverty-related diseases, including neglected ones;

· extend international cooperation with other public and private partners to ensure that the impact of all research is maximised and that synergies can be taken into consideration and achieve leveraging of resources and investments.

In order to reach the specific objectives, operational indicators and objectives would be monitored during the course of the EDCTP2 programme.

Agreements between the Union and the EDCTP2-IS : these must set out provisions for the publication of calls for proposals by EDCTP2, in particular on the single portal for participants as well as through other Horizon 2020 electronic means of dissemination managed by the Commission.

Audits : administrative burdens should be reduced for all parties. Double audits and disproportionate documentation and reporting should be avoided.

Evaluation : the Commission must carry out, with the assistance of independent experts, an interim evaluation of the EDCTP2 Programme by 30 June 2017 and report to Parliament and Council by 31 December 2017. The results of the independent interim evaluation should be taken into account in the interim evaluation of Horizon 2020.

Documents
2014/01/29
   EP - Committee report tabled for plenary, 1st reading/single reading
Details

The Committee on Industry, Research and Energy adopted the report by Vicky FORD (ECR, UK) on the proposal for a decision of the European Parliament and of the Council on the participation of the Union in a second European and Developing Countries Clinical Trials Partnership Programme (EDCTP2) jointly undertaken by several Member States.

The parliamentary committee recommended that the position adopted by the European Parliament at first reading under the ordinary legislative procedure should amend the Commission’s proposal as follows:

Union's financial contribution : this shall be EUR 648.85 million (as opposed to EUR 683 million in the Commission proposal) matching the contributions of the participating states. This contribution shall be paid from the appropriations in the general budget of the Union allocated to the relevant parts of the Specific Programme implementing Horizon 2020 Framework Programmeand, in particular, from the appropriations under the specific objective “Health, demographic change and wellbeing”.

Scope : Members suggested changing and extending the current scope of EDCTP1:

further strengthening the capabilities in developing countries for sound conduct and management of clinical trials, in particular, the role and development of ethical review committees and the corresponding regulatory environment, the coordination, collaboration and, where appropriate; extending public-private partnerships (P2Ps) such as the Product Development Partnerships (PDPs), civil society, non-governmental organisations and foundations; making the rules of governance more clear and transparent.

Activities of the programme EDCTP2 : the activities may include activities undertaken by public or private not-for-profit research organisations included in the national programme activities of participating states.

These activities must also contribute to:

supporting clinical trial research and related activities on poverty-related diseases, in particular, HIV/AIDS, malaria, tuberculosis and other poverty related and neglected diseases , devoting special attention to neglected diseases that are already affecting Sub-Saharan Africa and Europe; launching joint actions with industry and product development partnerships , aiming at reinforcing national health systems and facilitating transfers of results to the population concerned; assuring awareness, endorsement and acknowledgment of the EDCTP2 Programme and its activities through advocacy and communication, not only at European Union level and in developing countries, but also at global level.

Conditions applicable to the Union’s financial contribution : Members stressed the need to ensure that there be a strong coherence between the activities of the P2Ps and the research priorities defined in the Horizon 2020 Framework Programme, such as open access, equality between men and women and non-discrimination.

Rules for the participation and dissemination of results : an amendment sought to clearly establish that the Rules of Procedure apply and that projects are integrated and selected via competitive calls .

Members requested that all calls and opportunities to participate be widely advertised, including on the Commission's Horizon 2020 website which shall include a chapter dedicated to EDCTP2 .

Audits : without prejudice to the independence or the role of the Court of Auditors of the European Union, the Commission may, in duly reasoned cases and in consultation with the participating states, decide to carry out ex post audits of indirect activities itself.

Evaluation : the Commission shall organise an independent interim evaluation of the EDCTP2 Programme by 30 June 2017 and send that report to the European Parliament and to the Council by 31 December 2017. The result of the independent interim evaluation of EDCTP2 shall be taken into account in the interim evaluation of Horizon 2020.

In order to respond to unforeseen situations or to new developments and needs the Commission may, following the interim evaluation of Horizon 2020, review, within the annual budgetary procedure, the budget of EDCTP2.

Documents
2014/01/23
   EP - Vote in committee, 1st reading/single reading
2013/12/18
   EP - Committee opinion
Documents
2013/12/05
   EP - Amendments tabled in committee
Documents
2013/12/03
   CSL - Council Meeting
2013/11/12
   EP - Committee draft report
Documents
2013/11/11
   EP - PONGA Maurice (PPE) appointed as rapporteur in DEVE
2013/10/25
   ES_PARLIAMENT - Contribution
Documents
2013/10/17
   PT_PARLIAMENT - Contribution
Documents
2013/10/14
   EP - FORD Vicky (ECR) appointed as rapporteur in ITRE
2013/10/10
   IT_SENATE - Contribution
Documents
2013/09/26
   CSL - Debate in Council
Documents
2013/09/26
   CSL - Council Meeting
2013/09/10
   EP - Committee referral announced in Parliament, 1st reading/single reading
2013/07/10
   EC - Document attached to the procedure
2013/07/10
   EC - Document attached to the procedure
2013/07/10
   EC - Legislative proposal published
Details

PURPOSE: to enable the participation of the Union in a second European and Developing Countries Clinical Trials Partnership Programme jointly undertaken by several Member States.

PROPOSED ACT: Decision of the European Parliament and of the Council.

ROLE OF THE EUROPEAN PARLIAMENT: the European Parliament decides in accordance with the ordinary legislative procedure and on an equal footing with the Council.

BACKGROUND: the European and Developing Countries Clinical Trials Partnership (EDCTP) was established in 2003 in response to the global health crisis caused by the three main poverty-related diseases - HIV/AIDS, malaria and tuberculosis - and to the EU’s commitment to achieving the United Nation’s Millennium Development Goals by 2015. The first EDCTP programme (EDCTP-I 2003-2012) is now beyond its active funding period.

EDCTP-I had major achievements and has so far developed eight improved medical treatments, in particular for new-borns, children or pregnant/lactating women suffering from HIV/AIDS or malaria. It has resulted in the launch of the first four African Regional Networks of Excellence promoting South-South cooperation on clinical research and more than 400 African researchers have been trained. It has also contributed to establishing the Pan-African Clinical Trials Registry and the African Vaccine Regulators Forum.

Despite the results and impact of EDCTP so far, the health and socio-economic burden of poverty-related diseases persists and hinders the sustainable development of developing countries, in particular in sub-Saharan Africa . More than one billion people, including 400 million children, are suffering from one or more poverty-related diseases, including neglected infectious diseases such as sleeping sickness and worm infections. HIV/AIDS alone kills an estimated 2 million people, while malaria and tuberculosis together kill an estimated 2.2 million people annually.

Following the recommendations from the independent interim evaluation of EDCTP-I, the Belgian EU Council Presidency proposed, in November 2010, the launch of a second EDCTP joint programme (EDCTP-2) with at least ten years duration (2014-2024). On 15 June 2010, the European Parliament adopted a resolution on progress towards achieving the Millennium Development Goals (MDG) in which it ‘asks the Commission, the Member States and developing countries to address MDG 5 (on improving maternal health), MDG 4 (on child mortality) and MDG 6 (on HIV/AIDS, malaria and tuberculosis) in a coherent and holistic way’.

IMPACT ASSESSMENT: the external interim evaluations of the EDCTP-I and the impact assessment of the future EDCTP-2 programme call for the programme to be continued but with the next programme lasting 10 years and covering a scope that extends to other poverty-related diseases (beyond HIV/AIDS, tuberculosis and malaria) and to all phases of clinical development. The geographical focus should continue to be on sub-Saharan Africa.

LEGAL BASIS: Articles 185 and Article 188(2) of the Treaty on the Functioning of the European Union (TFEU).

CONTENT: the proposal for a decision concerns the participation of the Union in a second European and Developing Countries Clinical Trials Partnership Programme (EDCTP-2 ) jointly undertaken by Belgium, Denmark, Germany, Ireland, Greece, Spain, France, Italy, Luxembourg, the Netherlands, Austria, Portugal, Sweden and the United Kingdom, as well as Switzerland and Norway.

EDCTP2 shall contribute to the reduction of the social and economic burden of poverty-related diseases in developing countries, in particular in sub-Saharan Africa, by accelerating the clinical development of effective, safe and affordable medical interventions for poverty-related diseases, in partnership with sub-Saharan Africa.

EDCTP-2 seeks to achieve the following specific objectives:

an increased number of new or improved medical interventions for HIV/AIDS, tuberculosis, malaria and other poverty-related diseases, and by the end of the programme to have delivered (i) at least one new medical intervention; (ii) to have issued at least 30 guidelines for improved or extended use of existing medical interventions; and (iii) to have progressed the clinical development of at least 20 candidate medical interventions; strengthened cooperation with sub-Saharan African countries, in particular on building their capacity for conducting clinical trials; better coordination, alignment and integration of relevant national programmes to increase the cost-effectiveness of European public investments; extended international cooperation with other public and private funders; an increased impact due to effective cooperation with relevant European Union initiatives, including its development assistance.

EDCTP-2 has been conceived to complement the actions implemented under the European Development Funds and the Development Cooperation Instruments, and to respond to the Union’s commitment to the 2012 Rio+20 conference conclusions on developing and achieving internationally agreed Sustainable Development Goals.

BUDGETARY IMPLICATION: the Union contribution shall be up to EUR 683 million at current prices including EFTA contribution. The envelope is in current prices. The Union contribution shall be made from the ‘Health, demographic change and wellbeing’ challenge, DG Research & Innovation envelope, as part of the implementation of Horizon 2020 – The Framework Programme for Research and Innovation. The maximum amount of Union contribution for administrative costs is up to EUR 41 million.

Documents

Votes

A7-0064/2014 - Vicky Ford - Résolution législative

2014/04/15 Outcome: +: 646, -: 13, 0: 12
DE FR IT GB ES PL RO CZ BE SE HU NL PT BG AT SK FI LT HR IE LV DK LU SI EE EL MT CY
Total
96
68
56
66
47
44
29
22
20
20
18
26
16
15
16
13
12
11
11
11
8
11
6
6
6
8
4
4
icon: PPE PPE
234

Czechia PPE

2

Denmark PPE

For (1)

1

Luxembourg PPE

3

Estonia PPE

For (1)

1

Malta PPE

For (1)

1

Cyprus PPE

1
icon: S&D S&D
171

Netherlands S&D

3

Finland S&D

2

Ireland S&D

2

Luxembourg S&D

For (1)

1

Estonia S&D

For (1)

1
icon: ALDE ALDE
74

Slovakia ALDE

For (1)

1

Latvia ALDE

For (1)

1
3

Luxembourg ALDE

For (1)

1

Slovenia ALDE

2
icon: Verts/ALE Verts/ALE
55

United Kingdom Verts/ALE

5

Netherlands Verts/ALE

3

Portugal Verts/ALE

For (1)

1

Austria Verts/ALE

2

Finland Verts/ALE

2

Latvia Verts/ALE

1

Denmark Verts/ALE

For (1)

1

Luxembourg Verts/ALE

For (1)

1

Estonia Verts/ALE

For (1)

1
icon: ECR ECR
53

Belgium ECR

For (1)

1

Netherlands ECR

For (1)

1

Lithuania ECR

1

Croatia ECR

For (1)

1

Latvia ECR

For (1)

1
icon: GUE/NGL GUE/NGL
30

France GUE/NGL

Abstain (1)

4

United Kingdom GUE/NGL

1

Sweden GUE/NGL

1

Netherlands GUE/NGL

2

Portugal GUE/NGL

3

Croatia GUE/NGL

1

Ireland GUE/NGL

Against (1)

1

Latvia GUE/NGL

For (1)

1

Denmark GUE/NGL

Abstain (1)

1

Greece GUE/NGL

2

Cyprus GUE/NGL

1
icon: EFD EFD
26

France EFD

Against (1)

1

Belgium EFD

For (1)

1

Netherlands EFD

For (1)

1

Bulgaria EFD

For (1)

1

Slovakia EFD

For (1)

1

Finland EFD

For (1)

1

Lithuania EFD

2

Denmark EFD

Against (1)

1

Greece EFD

1
icon: NI NI
27

Italy NI

2
6

Spain NI

1

Belgium NI

For (1)

1

Hungary NI

Abstain (1)

1

Ireland NI

For (1)

1
AmendmentsDossier
145 2013/0243(COD)
2013/12/03 DEVE 38 amendments...
source: PE-524.736
2013/12/05 ITRE 107 amendments...
source: PE-522.974

History

(these mark the time of scraping, not the official date of the change)

committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Industry, Research and Energy
committee
ITRE
rapporteur
name: FORD Vicky date: 2013-10-14T00:00:00 group: European Conservatives and Reformists abbr: ECR
shadows
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Industry, Research and Energy
committee
ITRE
date
2013-10-14T00:00:00
rapporteur
name: FORD Vicky group: European Conservatives and Reformists abbr: ECR
shadows
committees/1
type
Committee Opinion
body
EP
associated
False
committee_full
Development
committee
DEVE
rapporteur
name: PONGA Maurice date: 2013-11-11T00:00:00 group: European People's Party (Christian Democrats) abbr: PPE
committees/1
type
Committee Opinion
body
EP
associated
False
committee_full
Development
committee
DEVE
date
2013-11-11T00:00:00
rapporteur
name: PONGA Maurice group: European People's Party (Christian Democrats) abbr: PPE
docs/6/body
EC
events/4/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2014-0064&language=EN
New
http://www.europarl.europa.eu/doceo/document/A-7-2014-0064_EN.html
events/6/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2014-0366
New
http://www.europarl.europa.eu/doceo/document/TA-7-2014-0366_EN.html
activities
  • date: 2013-07-10T00:00:00 docs: url: http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2013/0498/COM_COM(2013)0498_EN.pdf title: COM(2013)0498 type: Legislative proposal published celexid: CELEX:52013PC0498:EN body: EC commission: DG: url: http://ec.europa.eu/research/home.cfm title: Research and Innovation Commissioner: GEOGHEGAN-QUINN Máire type: Legislative proposal published
  • date: 2013-09-10T00:00:00 body: EP type: Committee referral announced in Parliament, 1st reading/single reading committees: body: EP responsible: False committee_full: Budgets committee: BUDG body: EP responsible: False committee: DEVE date: 2013-11-11T00:00:00 committee_full: Development rapporteur: group: PPE name: PONGA Maurice body: EP responsible: False committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP shadows: group: PPE name: CARVALHO Maria Da Graça group: S&D name: RIERA MADURELL Teresa group: ALDE name: HALL Fiona group: Verts/ALE name: RIVASI Michèle responsible: True committee: ITRE date: 2013-10-14T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: ECR name: FORD Vicky
  • body: CSL meeting_id: 3258 docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=3258*&MEET_DATE=26/09/2013 type: Debate in Council title: 3258 council: Competitiveness (Internal Market, Industry, Research and Space) date: 2013-09-26T00:00:00 type: Council Meeting
  • date: 2013-12-03T00:00:00 body: CSL type: Council Meeting council: Competitiveness (Internal Market, Industry, Research and Space) meeting_id: 3276
  • date: 2014-01-23T00:00:00 body: EP type: Vote in committee, 1st reading/single reading committees: body: EP responsible: False committee_full: Budgets committee: BUDG body: EP responsible: False committee: DEVE date: 2013-11-11T00:00:00 committee_full: Development rapporteur: group: PPE name: PONGA Maurice body: EP responsible: False committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP shadows: group: PPE name: CARVALHO Maria Da Graça group: S&D name: RIERA MADURELL Teresa group: ALDE name: HALL Fiona group: Verts/ALE name: RIVASI Michèle responsible: True committee: ITRE date: 2013-10-14T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: ECR name: FORD Vicky
  • body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2014-0064&language=EN type: Committee report tabled for plenary, 1st reading/single reading title: A7-0064/2014 type: Committee report tabled for plenary, 1st reading/single reading committees: body: EP responsible: False committee_full: Budgets committee: BUDG body: EP responsible: False committee: DEVE date: 2013-11-11T00:00:00 committee_full: Development rapporteur: group: PPE name: PONGA Maurice body: EP responsible: False committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP shadows: group: PPE name: CARVALHO Maria Da Graça group: S&D name: RIERA MADURELL Teresa group: ALDE name: HALL Fiona group: Verts/ALE name: RIVASI Michèle responsible: True committee: ITRE date: 2013-10-14T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: ECR name: FORD Vicky date: 2014-01-29T00:00:00
  • date: 2014-04-15T00:00:00 docs: url: http://www.europarl.europa.eu/oeil/popups/sda.do?id=24077&l=en type: Results of vote in Parliament title: Results of vote in Parliament url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2014-0366 type: Decision by Parliament, 1st reading/single reading title: T7-0366/2014 body: EP type: Results of vote in Parliament
  • date: 2014-05-06T00:00:00 body: CSL type: Council Meeting council: Economic and Financial Affairs ECOFIN meeting_id: 3310
  • date: 2014-05-06T00:00:00 body: EP/CSL type: Act adopted by Council after Parliament's 1st reading
  • date: 2014-05-15T00:00:00 body: CSL type: Final act signed
  • date: 2014-05-15T00:00:00 body: EP type: End of procedure in Parliament
  • date: 2014-06-07T00:00:00 type: Final act published in Official Journal docs: url: http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32014D0556 title: Decision 2014/556 url: http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2014:169:TOC title: OJ L 169 07.06.2014, p. 0038
commission
  • body: EC dg: Research and Innovation commissioner: GEOGHEGAN-QUINN Máire
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Industry, Research and Energy
committee
ITRE
date
2013-10-14T00:00:00
rapporteur
name: FORD Vicky group: European Conservatives and Reformists abbr: ECR
shadows
committees/0
body
EP
responsible
False
committee_full
Budgets
committee
BUDG
committees/1
type
Committee Opinion
body
EP
associated
False
committee_full
Development
committee
DEVE
date
2013-11-11T00:00:00
rapporteur
name: PONGA Maurice group: European People's Party (Christian Democrats) abbr: PPE
committees/1
body
EP
responsible
False
committee
DEVE
date
2013-11-11T00:00:00
committee_full
Development
rapporteur
group: PPE name: PONGA Maurice
committees/2
type
Committee Opinion
body
EP
associated
False
committee_full
Budgets
committee
BUDG
opinion
False
committees/2
body
EP
responsible
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
committees/3
type
Committee Opinion
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
opinion
False
committees/3
body
EP
shadows
responsible
True
committee
ITRE
date
2013-10-14T00:00:00
committee_full
Industry, Research and Energy
rapporteur
group: ECR name: FORD Vicky
council
  • body: CSL type: Council Meeting council: Economic and Financial Affairs ECOFIN meeting_id: 3310 url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=3310*&MEET_DATE=06/05/2014 date: 2014-05-06T00:00:00
  • body: CSL type: Council Meeting council: Competitiveness (Internal Market, Industry, Research and Space) meeting_id: 3276 url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=3276*&MEET_DATE=03/12/2013 date: 2013-12-03T00:00:00
  • body: CSL type: Council Meeting council: Competitiveness (Internal Market, Industry, Research and Space) meeting_id: 3258 url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=3258*&MEET_DATE=26/09/2013 date: 2013-09-26T00:00:00
docs
  • date: 2013-07-10T00:00:00 docs: url: https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=SWD:2013:0253:FIN:EN:PDF title: EUR-Lex title: SWD(2013)0253 type: Document attached to the procedure body: EC
  • date: 2013-07-10T00:00:00 docs: url: https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=SWD:2013:0254:FIN:EN:PDF title: EUR-Lex title: SWD(2013)0254 type: Document attached to the procedure body: EC
  • date: 2013-11-12T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE522.973 title: PE522.973 type: Committee draft report body: EP
  • date: 2013-12-05T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE522.974 title: PE522.974 type: Amendments tabled in committee body: EP
  • date: 2013-12-18T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE521.824&secondRef=02 title: PE521.824 committee: DEVE type: Committee opinion body: EP
  • date: 2014-05-15T00:00:00 docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=[%n4]%2F14&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC title: 00054/2014/LEX type: Draft final act body: CSL
  • date: 2014-07-09T00:00:00 docs: url: /oeil/spdoc.do?i=24077&j=0&l=en title: SP(2014)471 type: Commission response to text adopted in plenary
  • date: 2013-10-25T00:00:00 docs: url: http://www.connefof.europarl.europa.eu/connefof/app/exp/COM(2013)0498 title: COM(2013)0498 type: Contribution body: ES_PARLIAMENT
  • date: 2013-10-10T00:00:00 docs: url: http://www.connefof.europarl.europa.eu/connefof/app/exp/COM(2013)0498 title: COM(2013)0498 type: Contribution body: IT_SENATE
  • date: 2013-10-17T00:00:00 docs: url: http://www.connefof.europarl.europa.eu/connefof/app/exp/COM(2013)0498 title: COM(2013)0498 type: Contribution body: PT_PARLIAMENT
events
  • date: 2013-07-10T00:00:00 type: Legislative proposal published body: EC docs: url: http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2013/0498/COM_COM(2013)0498_EN.pdf title: COM(2013)0498 url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=2013&nu_doc=498 title: EUR-Lex summary: PURPOSE: to enable the participation of the Union in a second European and Developing Countries Clinical Trials Partnership Programme jointly undertaken by several Member States. PROPOSED ACT: Decision of the European Parliament and of the Council. ROLE OF THE EUROPEAN PARLIAMENT: the European Parliament decides in accordance with the ordinary legislative procedure and on an equal footing with the Council. BACKGROUND: the European and Developing Countries Clinical Trials Partnership (EDCTP) was established in 2003 in response to the global health crisis caused by the three main poverty-related diseases - HIV/AIDS, malaria and tuberculosis - and to the EU’s commitment to achieving the United Nation’s Millennium Development Goals by 2015. The first EDCTP programme (EDCTP-I 2003-2012) is now beyond its active funding period. EDCTP-I had major achievements and has so far developed eight improved medical treatments, in particular for new-borns, children or pregnant/lactating women suffering from HIV/AIDS or malaria. It has resulted in the launch of the first four African Regional Networks of Excellence promoting South-South cooperation on clinical research and more than 400 African researchers have been trained. It has also contributed to establishing the Pan-African Clinical Trials Registry and the African Vaccine Regulators Forum. Despite the results and impact of EDCTP so far, the health and socio-economic burden of poverty-related diseases persists and hinders the sustainable development of developing countries, in particular in sub-Saharan Africa . More than one billion people, including 400 million children, are suffering from one or more poverty-related diseases, including neglected infectious diseases such as sleeping sickness and worm infections. HIV/AIDS alone kills an estimated 2 million people, while malaria and tuberculosis together kill an estimated 2.2 million people annually. Following the recommendations from the independent interim evaluation of EDCTP-I, the Belgian EU Council Presidency proposed, in November 2010, the launch of a second EDCTP joint programme (EDCTP-2) with at least ten years duration (2014-2024). On 15 June 2010, the European Parliament adopted a resolution on progress towards achieving the Millennium Development Goals (MDG) in which it ‘asks the Commission, the Member States and developing countries to address MDG 5 (on improving maternal health), MDG 4 (on child mortality) and MDG 6 (on HIV/AIDS, malaria and tuberculosis) in a coherent and holistic way’. IMPACT ASSESSMENT: the external interim evaluations of the EDCTP-I and the impact assessment of the future EDCTP-2 programme call for the programme to be continued but with the next programme lasting 10 years and covering a scope that extends to other poverty-related diseases (beyond HIV/AIDS, tuberculosis and malaria) and to all phases of clinical development. The geographical focus should continue to be on sub-Saharan Africa. LEGAL BASIS: Articles 185 and Article 188(2) of the Treaty on the Functioning of the European Union (TFEU). CONTENT: the proposal for a decision concerns the participation of the Union in a second European and Developing Countries Clinical Trials Partnership Programme (EDCTP-2 ) jointly undertaken by Belgium, Denmark, Germany, Ireland, Greece, Spain, France, Italy, Luxembourg, the Netherlands, Austria, Portugal, Sweden and the United Kingdom, as well as Switzerland and Norway. EDCTP2 shall contribute to the reduction of the social and economic burden of poverty-related diseases in developing countries, in particular in sub-Saharan Africa, by accelerating the clinical development of effective, safe and affordable medical interventions for poverty-related diseases, in partnership with sub-Saharan Africa. EDCTP-2 seeks to achieve the following specific objectives: an increased number of new or improved medical interventions for HIV/AIDS, tuberculosis, malaria and other poverty-related diseases, and by the end of the programme to have delivered (i) at least one new medical intervention; (ii) to have issued at least 30 guidelines for improved or extended use of existing medical interventions; and (iii) to have progressed the clinical development of at least 20 candidate medical interventions; strengthened cooperation with sub-Saharan African countries, in particular on building their capacity for conducting clinical trials; better coordination, alignment and integration of relevant national programmes to increase the cost-effectiveness of European public investments; extended international cooperation with other public and private funders; an increased impact due to effective cooperation with relevant European Union initiatives, including its development assistance. EDCTP-2 has been conceived to complement the actions implemented under the European Development Funds and the Development Cooperation Instruments, and to respond to the Union’s commitment to the 2012 Rio+20 conference conclusions on developing and achieving internationally agreed Sustainable Development Goals. BUDGETARY IMPLICATION: the Union contribution shall be up to EUR 683 million at current prices including EFTA contribution. The envelope is in current prices. The Union contribution shall be made from the ‘Health, demographic change and wellbeing’ challenge, DG Research & Innovation envelope, as part of the implementation of Horizon 2020 – The Framework Programme for Research and Innovation. The maximum amount of Union contribution for administrative costs is up to EUR 41 million.
  • date: 2013-09-10T00:00:00 type: Committee referral announced in Parliament, 1st reading/single reading body: EP
  • date: 2013-09-26T00:00:00 type: Debate in Council body: CSL docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=3258*&MEET_DATE=26/09/2013 title: 3258
  • date: 2014-01-23T00:00:00 type: Vote in committee, 1st reading/single reading body: EP
  • date: 2014-01-29T00:00:00 type: Committee report tabled for plenary, 1st reading/single reading body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2014-0064&language=EN title: A7-0064/2014 summary: The Committee on Industry, Research and Energy adopted the report by Vicky FORD (ECR, UK) on the proposal for a decision of the European Parliament and of the Council on the participation of the Union in a second European and Developing Countries Clinical Trials Partnership Programme (EDCTP2) jointly undertaken by several Member States. The parliamentary committee recommended that the position adopted by the European Parliament at first reading under the ordinary legislative procedure should amend the Commission’s proposal as follows: Union's financial contribution : this shall be EUR 648.85 million (as opposed to EUR 683 million in the Commission proposal) matching the contributions of the participating states. This contribution shall be paid from the appropriations in the general budget of the Union allocated to the relevant parts of the Specific Programme implementing Horizon 2020 Framework Programmeand, in particular, from the appropriations under the specific objective “Health, demographic change and wellbeing”. Scope : Members suggested changing and extending the current scope of EDCTP1: further strengthening the capabilities in developing countries for sound conduct and management of clinical trials, in particular, the role and development of ethical review committees and the corresponding regulatory environment, the coordination, collaboration and, where appropriate; extending public-private partnerships (P2Ps) such as the Product Development Partnerships (PDPs), civil society, non-governmental organisations and foundations; making the rules of governance more clear and transparent. Activities of the programme EDCTP2 : the activities may include activities undertaken by public or private not-for-profit research organisations included in the national programme activities of participating states. These activities must also contribute to: supporting clinical trial research and related activities on poverty-related diseases, in particular, HIV/AIDS, malaria, tuberculosis and other poverty related and neglected diseases , devoting special attention to neglected diseases that are already affecting Sub-Saharan Africa and Europe; launching joint actions with industry and product development partnerships , aiming at reinforcing national health systems and facilitating transfers of results to the population concerned; assuring awareness, endorsement and acknowledgment of the EDCTP2 Programme and its activities through advocacy and communication, not only at European Union level and in developing countries, but also at global level. Conditions applicable to the Union’s financial contribution : Members stressed the need to ensure that there be a strong coherence between the activities of the P2Ps and the research priorities defined in the Horizon 2020 Framework Programme, such as open access, equality between men and women and non-discrimination. Rules for the participation and dissemination of results : an amendment sought to clearly establish that the Rules of Procedure apply and that projects are integrated and selected via competitive calls . Members requested that all calls and opportunities to participate be widely advertised, including on the Commission's Horizon 2020 website which shall include a chapter dedicated to EDCTP2 . Audits : without prejudice to the independence or the role of the Court of Auditors of the European Union, the Commission may, in duly reasoned cases and in consultation with the participating states, decide to carry out ex post audits of indirect activities itself. Evaluation : the Commission shall organise an independent interim evaluation of the EDCTP2 Programme by 30 June 2017 and send that report to the European Parliament and to the Council by 31 December 2017. The result of the independent interim evaluation of EDCTP2 shall be taken into account in the interim evaluation of Horizon 2020. In order to respond to unforeseen situations or to new developments and needs the Commission may, following the interim evaluation of Horizon 2020, review, within the annual budgetary procedure, the budget of EDCTP2.
  • date: 2014-04-15T00:00:00 type: Results of vote in Parliament body: EP docs: url: https://oeil.secure.europarl.europa.eu/oeil/popups/sda.do?id=24077&l=en title: Results of vote in Parliament
  • date: 2014-04-15T00:00:00 type: Decision by Parliament, 1st reading/single reading body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2014-0366 title: T7-0366/2014 summary: The European Parliament adopted by 646 votes to 13, with 12 abstentions, a legislative resolution on the proposal for a decision of the European Parliament and of the Council on the participation of the Union in a second European and Developing Countries Clinical Trials Partnership Programme (EDCTP2) jointly undertaken by several Member States. Parliament adopted its position at first reading under the ordinary legislative procedure. The amendments adopted in plenary were the result of a compromise between Parliament and Council. They amend the Commission’s proposal as follows: Union financial contribution : as stated in the Commission proposal, this would be EUR 683 million, to equal the contributions of Participating States. It will be paid from the appropriations in the general budget of the Union allocated to the relevant parts of the Specific Programme implementing Horizon 2020 , and in particular from the appropriations under the specific objective " Health, demographic change and wellbeing ". To take account of the duration of the Horizon 2020 Programme, all calls for proposals should be launched by 31 December 2020 . Scope: in the Communication of 27 February 2013 entitled "A decent life for all: ending poverty and giving the world a sustainable future", the Commission reaffirmed its commitment to doing its utmost to help achieve the MDG by 2015, and pointed out that EU-funded research under EDCTP1 had contributed to achieving the MDG. Parliament and Council agreed to amend and extend the current scope of EDCTP1 by : · strengthening the capabilities in developing countries for the sound conduct and management of clinical trials, in particular the role and development of ethical review committees and the corresponding regulatory environment, the coordination, collaboration and, where appropriate, improving integration of European national programmes ; · extending collaboration with other major public and private partners, including the pharmaceutical industry, and public-private partnerships such as the Product Development Partnerships ("PDPs"), civil society, non-governmental organisations and foundations; · ensuring clear and transparent rules of governance. EDCTP2 activities : activities may include activities undertaken by public or private not-for-profit research organisations, and new activities, including calls for proposals managed by the EDCTP2-IS. The programme should contribute to the reduction of the social and economic burden of poverty-related diseases in developing countries, and in particular in sub-Saharan Africa, by accelerating the clinical development of effective, safe, accessible, suitable and affordable medical interventions for such diseases, (such as drugs, microbicides or vaccines, including their delivery modality, follow up of treatment and prevention in the affected population as well as medical diagnostics to detect and monitor disease/health evolution.) The specific objectives will be, inter alia : · an increased number of new or improved medical interventions for HIV/AIDS, tuberculosis, malaria and other poverty-related diseases, including neglected ones , and by the end of the programme to have delivered at least one new medical intervention, issued approximately 30 guidelines, and have progressed the clinical development of approximately 20 candidate medical interventions; · establish the research priorities in an objective-orientated manner in order to accelerate results and contribute to the control and eradication of poverty-related diseases, including neglected ones; · extend international cooperation with other public and private partners to ensure that the impact of all research is maximised and that synergies can be taken into consideration and achieve leveraging of resources and investments. In order to reach the specific objectives, operational indicators and objectives would be monitored during the course of the EDCTP2 programme. Agreements between the Union and the EDCTP2-IS : these must set out provisions for the publication of calls for proposals by EDCTP2, in particular on the single portal for participants as well as through other Horizon 2020 electronic means of dissemination managed by the Commission. Audits : administrative burdens should be reduced for all parties. Double audits and disproportionate documentation and reporting should be avoided. Evaluation : the Commission must carry out, with the assistance of independent experts, an interim evaluation of the EDCTP2 Programme by 30 June 2017 and report to Parliament and Council by 31 December 2017. The results of the independent interim evaluation should be taken into account in the interim evaluation of Horizon 2020.
  • date: 2014-05-06T00:00:00 type: Act adopted by Council after Parliament's 1st reading body: EP/CSL
  • date: 2014-05-15T00:00:00 type: Final act signed body: CSL
  • date: 2014-05-15T00:00:00 type: End of procedure in Parliament body: EP
  • date: 2014-06-07T00:00:00 type: Final act published in Official Journal summary: PURPOSE: to contribute to the reduction of the social and economic burden of poverty-related diseases in developing countries, and in particular in sub-Saharan Africa. LEGISLATIVE ACT: Decision No 556/2014/EU of the European Parliament and of the Council on the participation of the Union in a second European and Developing Countries Clinical Trials Partnership Programme (EDCTP2) jointly undertaken by several Member States CONTENT: this Decision is part of a package of four legal acts for a new generation of public -private partnerships that will allow large-scale, long-term innovation projects to be carried out under the umbrella of Horizon 2020, the EU's research and innovation framework programme. Three other public-public partnerships will be further developed on research programmes jointly undertaken by Member States with the participation of the Union in the areas of: · a second research and development programme aimed at supporting research and development performing small and medium-sized enterprises (‘Eurostars-2’ ); · a programme on research and development on active and assisted living ( AAL programme ); · a European research and innovation programme on metrology ( EMPIR ) ; Objective: the Decision establishes the rules and conditions for Union participation in the second European and Developing Countries Clinical Trials Partnership Programme (the ‘EDCTP2 Programme’), jointly undertaken by Austria, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden, Switzerland and the United Kingdom. Any Member State and any other country associated to Horizon 2020 may apply to join the programme, provided it fulfils the conditions regarding financial contribution. Programme objectives : EDCTP1 (2003-2012) produced major achievements, and developed eight improved medical treatments, in particular for newborns, children and pregnant or breastfeeding women suffering from HIV/AIDS or malaria. In extending the first programme, EDCTP-II will contribute to the reduction of the social and economic burden of poverty-related diseases in developing countries, and in particular in sub-Saharan Africa, by accelerating the clinical development of effective, safe, accessible, suitable and affordable medical interventions for poverty-related diseases in partnership with sub-Saharan countries. The specific objectives are, inter alia: · an increased number of new or improved medical interventions for HIV/AIDS, tuberculosis, malaria and other poverty-related diseases , including neglected ones, and by the end of the programme to have delivered at least one new medical intervention; to have issued approximately 30 guidelines and approximately 20 candidate medical interventions; · strengthened cooperation with sub-Saharan African countries, in particular on building their capacity for conducting clinical trials in compliance with fundamental ethical principles and relevant national, Union and international legislation; · better coordination, alignment and, where appropriate, integration of relevant national programmes to increase the cost-effectiveness of European public investments; · extended international cooperation with other public and private partners to ensure that the impact of all research is maximised and that synergies can be taken into consideration and achieve leveraging of resources and investments. Union financial contribution: the Union’s financial contribution, including EFTA appropriations, to the EDCTP2 Programme shall be up to EUR 683 000 000 to equal the contributions of Participating States. This contribution shall be paid from the appropriations allocated to the relevant parts of the Specific Programme implementing Horizon 2020 , and in particular from the appropriations under the specific objective ‘Health, demographic change and wellbeing’. Implementation: the Participating States have agreed on the implementation structure for EDCTP2 Programme and have set up the EDCTP2-Implementation Structure (‘EDCTP2-IS’). The EDCTP2-IS should be the recipient of the Union’s financial contribution and should ensure the efficient implementation of the EDCTP2 Programme. Calls for proposals should be launched at the latest by 31 December 2020. In duly justified cases they may be launched by 31 December 2021. Calls for proposals should also be published on the single portal for participants as well as through other Horizon 2020 electronic means of dissemination managed by the Commission. In order to protect the Union’s financial interests , the Commission should have the right to reduce, suspend or terminate the Union’s financial contribution if the programme is implemented inadequately. Evaluation : by 30 June 2017, the Commission shall carry out an interim evaluation of EDCTP-II with the help of independent experts. It shall send that report to the European Parliament and to the Council by 31 December 2017. The result of the interim evaluation of the programme shall be taken into account in the interim evaluation of Horizon 2020. ENTRY INTO FORCE: 27.06.2014. docs: title: Decision 2014/556 url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32014D0556 title: OJ L 169 07.06.2014, p. 0038 url: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2014:169:TOC
other
  • body: CSL type: Council Meeting council: Former Council configuration
  • body: EC dg: url: http://ec.europa.eu/research/home.cfm title: Research and Innovation commissioner: GEOGHEGAN-QUINN Máire
otherinst
  • name: European Economic and Social Committee
procedure/Mandatory consultation of other institutions
Economic and Social Committee
procedure/Modified legal basis
Old
Rules of Procedure of the European Parliament EP 150
New
Rules of Procedure EP 150
procedure/dossier_of_the_committee
Old
ITRE/7/13414
New
  • ITRE/7/13414
procedure/final/url
Old
http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32014D0556
New
https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32014D0556
procedure/instrument
Old
Decision
New
  • Decision
  • See also 2011/0401(COD)
procedure/other_consulted_institutions
European Economic and Social Committee
procedure/subject
Old
  • 3.50.01.05 Research specific areas
  • 4.20.02.06 Clinical practice and experiments
  • 6.30.02 Financial and technical cooperation and assistance
New
3.50.01.05
Research specific areas
4.20.02.06
Clinical practice and experiments
6.30.02
Financial and technical cooperation and assistance
procedure/summary
  • See also
activities/0/docs/0/celexid
CELEX:52013PC0498:EN
activities/0/docs/0/celexid
CELEX:52013PC0498:EN
links/European Commission/title
Old
PreLex
New
EUR-Lex
activities/1/committees
  • body: EP responsible: False committee_full: Budgets committee: BUDG
  • body: EP responsible: False committee: DEVE date: 2013-11-11T00:00:00 committee_full: Development rapporteur: group: PPE name: PONGA Maurice
  • body: EP responsible: False committee_full: Environment, Public Health and Food Safety committee: ENVI
  • body: EP shadows: group: PPE name: CARVALHO Maria Da Graça group: S&D name: RIERA MADURELL Teresa group: ALDE name: HALL Fiona group: Verts/ALE name: RIVASI Michèle responsible: True committee: ITRE date: 2013-10-14T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: ECR name: FORD Vicky
activities/1/date
Old
2014-04-15T00:00:00
New
2013-09-10T00:00:00
activities/1/docs
  • url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2014-0366 type: Decision by Parliament, 1st reading/single reading title: T7-0366/2014
activities/1/type
Old
Decision by Parliament, 1st reading/single reading
New
Committee referral announced in Parliament, 1st reading/single reading
activities/4/committees/1/date
2013-11-11T00:00:00
activities/4/committees/1/rapporteur
  • group: PPE name: PONGA Maurice
activities/4/committees/3/date
2013-10-14T00:00:00
activities/4/committees/3/rapporteur
  • group: ECR name: FORD Vicky
activities/4/committees/3/shadows
  • group: PPE name: CARVALHO Maria Da Graça
  • group: S&D name: RIERA MADURELL Teresa
  • group: ALDE name: HALL Fiona
  • group: Verts/ALE name: RIVASI Michèle
activities/5/committees/1/date
2013-11-11T00:00:00
activities/5/committees/1/rapporteur
  • group: PPE name: PONGA Maurice
activities/5/committees/3/date
2013-10-14T00:00:00
activities/5/committees/3/rapporteur
  • group: ECR name: FORD Vicky
activities/5/committees/3/shadows
  • group: PPE name: CARVALHO Maria Da Graça
  • group: S&D name: RIERA MADURELL Teresa
  • group: ALDE name: HALL Fiona
  • group: Verts/ALE name: RIVASI Michèle
activities/6/committees
  • body: EP responsible: False committee_full: Budgets committee: BUDG
  • body: EP responsible: False committee_full: Development committee: DEVE
  • body: EP responsible: False committee_full: Environment, Public Health and Food Safety committee: ENVI
  • body: EP responsible: True committee_full: Industry, Research and Energy committee: ITRE
activities/6/date
Old
2013-09-10T00:00:00
New
2014-04-15T00:00:00
activities/6/docs
  • url: http://www.europarl.europa.eu/oeil/popups/sda.do?id=24077&l=en type: Results of vote in Parliament title: Results of vote in Parliament
  • url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2014-0366 type: Decision by Parliament, 1st reading/single reading title: T7-0366/2014
activities/6/type
Old
Committee referral announced in Parliament, 1st reading/single reading
New
Results of vote in Parliament
activities/11/docs/1/url
Old
http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32014D0556&from=EN
New
http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2014:169:TOC
activities/11/text
  • PURPOSE: to contribute to the reduction of the social and economic burden of poverty-related diseases in developing countries, and in particular in sub-Saharan Africa.

    LEGISLATIVE ACT: Decision No 556/2014/EU of the European Parliament and of the Council on the participation of the Union in a second European and Developing Countries Clinical Trials Partnership Programme (EDCTP2) jointly undertaken by several Member States

    CONTENT: this Decision is part of a package of four legal acts for a new generation of public -private partnerships that will allow large-scale, long-term innovation projects to be carried out under the umbrella of Horizon 2020, the EU's research and innovation framework programme.

    Three other public-public partnerships will be further developed on research programmes jointly undertaken by Member States with the participation of the Union in the areas of:

    ·        a second research and development programme aimed at supporting research and development performing small and medium-sized enterprises (‘Eurostars-2’);

    ·        a programme on research and development on active and assisted living (AAL programme);

    ·        a European research and innovation programme on metrology (EMPIR) ;

    Objective: the Decision establishes the rules and conditions for Union participation in the second European and Developing Countries Clinical Trials Partnership Programme (the ‘EDCTP2 Programme’), jointly undertaken by Austria, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden, Switzerland and the United Kingdom.

    Any Member State and any other country associated to Horizon 2020 may apply to join the programme, provided it fulfils the conditions regarding financial contribution. 

    Programme objectives: EDCTP1 (2003-2012) produced major achievements, and developed eight improved medical treatments, in particular for newborns, children and pregnant or breastfeeding women suffering from HIV/AIDS or malaria.

    In extending the first programme, EDCTP-II will contribute to the reduction of the social and economic burden of poverty-related diseases in developing countries, and in particular in sub-Saharan Africa, by accelerating the clinical development of effective, safe, accessible, suitable and affordable medical interventions for poverty-related diseases in partnership with sub-Saharan countries.

    The specific objectives are, inter alia:

    ·        an increased number of new or improved medical interventions for HIV/AIDS, tuberculosis, malaria and other poverty-related diseases, including neglected ones, and by the end of the programme to have delivered at least one new medical intervention; to have issued approximately 30 guidelines and approximately 20 candidate medical interventions;

    ·        strengthened cooperation with sub-Saharan African countries, in particular on building their capacity for conducting clinical trials in compliance with fundamental ethical principles and relevant national, Union and international legislation;

    ·        better coordination, alignment and, where appropriate, integration of relevant national programmes to increase the cost-effectiveness of European public investments;

    ·        extended international cooperation with other public and private partners to ensure that the impact of all research is maximised and that synergies can be taken into consideration and achieve leveraging of resources and investments.

    Union financial contribution: the Union’s financial contribution, including EFTA appropriations, to the EDCTP2 Programme shall be up to EUR 683 000 000 to equal the contributions of Participating States.

    This contribution shall be paid from the appropriations allocated to the relevant parts of the Specific Programme implementing Horizon 2020, and in particular from the appropriations under the specific objective ‘Health, demographic change and wellbeing’.

    Implementation: the Participating States have agreed on the implementation structure for EDCTP2 Programme and have set up the EDCTP2-Implementation Structure (‘EDCTP2-IS’). The EDCTP2-IS should be the recipient of the Union’s financial contribution and should ensure the efficient implementation of the EDCTP2 Programme.

    Calls for proposals should be launched at the latest by 31 December 2020. In duly justified cases they may be launched by 31 December 2021. Calls for proposals should also be published on the single portal for participants as well as through other Horizon 2020 electronic means of dissemination managed by the Commission.

    In order to protect the Union’s financial interests, the Commission should have the right to reduce, suspend or terminate the Union’s financial contribution if the programme is implemented inadequately.

    Evaluation: by 30 June 2017, the Commission shall carry out an interim evaluation of EDCTP-II with the help of independent experts. It shall send that report to the European Parliament and to the Council by 31 December 2017. The result of the interim evaluation of the programme shall be taken into account in the interim evaluation of Horizon 2020.

    ENTRY INTO FORCE: 27.06.2014.

committees/1/date
2013-11-11T00:00:00
committees/1/rapporteur
  • group: PPE name: PONGA Maurice
committees/3/date
2013-10-14T00:00:00
committees/3/rapporteur
  • group: ECR name: FORD Vicky
committees/3/shadows
  • group: PPE name: CARVALHO Maria Da Graça
  • group: S&D name: RIERA MADURELL Teresa
  • group: ALDE name: HALL Fiona
  • group: Verts/ALE name: RIVASI Michèle
activities/1/committees/1/date
2013-11-11T00:00:00
activities/1/committees/1/rapporteur
  • group: EPP name: PONGA Maurice
activities/1/committees/3/date
2013-10-14T00:00:00
activities/1/committees/3/rapporteur
  • group: ECR name: FORD Vicky
activities/1/committees/3/shadows
  • group: EPP name: CARVALHO Maria Da Graça
  • group: S&D name: RIERA MADURELL Teresa
  • group: ALDE name: HALL Fiona
  • group: Verts/ALE name: RIVASI Michèle
activities/4
date
2014-01-23T00:00:00
body
EP
type
Vote in committee, 1st reading/single reading
committees
activities/5/committees/1/date
2013-11-11T00:00:00
activities/5/committees/1/rapporteur
  • group: EPP name: PONGA Maurice
activities/5/committees/3/date
2013-10-14T00:00:00
activities/5/committees/3/rapporteur
  • group: ECR name: FORD Vicky
activities/5/committees/3/shadows
  • group: EPP name: CARVALHO Maria Da Graça
  • group: S&D name: RIERA MADURELL Teresa
  • group: ALDE name: HALL Fiona
  • group: Verts/ALE name: RIVASI Michèle
activities/11/body
EP
activities/11/committees
  • body: EP responsible: False committee_full: Budgets committee: BUDG
  • body: EP responsible: False committee: DEVE date: 2013-11-11T00:00:00 committee_full: Development rapporteur: group: EPP name: PONGA Maurice
  • body: EP responsible: False committee_full: Environment, Public Health and Food Safety committee: ENVI
  • body: EP shadows: group: EPP name: CARVALHO Maria Da Graça group: S&D name: RIERA MADURELL Teresa group: ALDE name: HALL Fiona group: Verts/ALE name: RIVASI Michèle responsible: True committee: ITRE date: 2013-10-14T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: ECR name: FORD Vicky
activities/11/date
Old
2014-01-23T00:00:00
New
2014-06-07T00:00:00
activities/11/docs
  • url: http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32014D0556 title: Decision 2014/556
  • url: http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32014D0556&from=EN title: OJ L 169 07.06.2014, p. 0038
activities/11/type
Old
Vote in committee, 1st reading/single reading
New
Final act published in Official Journal
committees/1/date
2013-11-11T00:00:00
committees/1/rapporteur
  • group: EPP name: PONGA Maurice
committees/3/date
2013-10-14T00:00:00
committees/3/rapporteur
  • group: ECR name: FORD Vicky
committees/3/shadows
  • group: EPP name: CARVALHO Maria Da Graça
  • group: S&D name: RIERA MADURELL Teresa
  • group: ALDE name: HALL Fiona
  • group: Verts/ALE name: RIVASI Michèle
procedure/Modified legal basis
Rules of Procedure of the European Parliament EP 150
procedure/final
url
http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32014D0556
title
Decision 2014/556
procedure/stage_reached
Old
Procedure completed, awaiting publication in Official Journal
New
Procedure completed
procedure/title
Old
Second European and Developing Countries Clinical Trials Partnership Programme: participation of the Union
New
Second European and Developing Countries Clinical Trials Partnership Programme (EDCTP2): participation of the Union
activities/10
date
2014-05-15T00:00:00
body
EP
type
End of procedure in Parliament
activities/9
date
2014-05-15T00:00:00
body
CSL
type
Final act signed
procedure/stage_reached
Old
Awaiting signature of act
New
Procedure completed, awaiting publication in Official Journal
activities/6/docs/0/url
http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2014-0366
activities/6/docs/0/text
  • The European Parliament adopted by 646 votes to 13, with 12 abstentions, a legislative resolution on the proposal for a decision of the European Parliament and of the Council on the participation of the Union in a second European and Developing Countries Clinical Trials Partnership Programme (EDCTP2) jointly undertaken by several Member States.

    Parliament adopted its position at first reading under the ordinary legislative procedure. The amendments adopted in plenary were the result of a compromise between Parliament and Council. They amend the Commission’s proposal as follows:

    Union financial contribution: as stated in the Commission proposal, this would be EUR 683 million, to equal the contributions of Participating States.

    It will be paid from the appropriations in the general budget of the Union allocated to the relevant parts of the Specific Programme implementing Horizon 2020, and in particular from the appropriations under the specific objective "Health, demographic change and wellbeing".

    To take account of the duration of the Horizon 2020 Programme, all calls for proposals should be launched by 31 December 2020

    Scope: in the Communication of 27 February 2013 entitled "A decent life for all: ending poverty and giving the world a sustainable future", the Commission reaffirmed its commitment to doing its utmost to help achieve the MDG by 2015, and pointed out that EU-funded research under EDCTP1 had contributed to achieving the MDG.

    Parliament and Council agreed to amend and extend the current scope of EDCTP1 by :

    ·        strengthening the capabilities in developing countries for the sound conduct and management of clinical trials, in particular the role and development of ethical review committees and the corresponding regulatory environment, the coordination, collaboration and, where appropriate, improving integration of European national programmes ;

    ·        extending collaboration with other major public and private partners, including the pharmaceutical industry, and public-private partnerships such as the Product Development Partnerships ("PDPs"), civil society, non-governmental organisations and foundations;

    ·        ensuring clear and transparent rules of governance.

    EDCTP2 activities: activities may include activities undertaken by public or private not-for-profit research organisations, and new activities, including calls for proposals managed by the EDCTP2-IS.

    The programme should contribute to the reduction of the social and economic burden of poverty-related diseases in developing countries, and in particular in sub-Saharan Africa, by accelerating the clinical development of effective, safe, accessible, suitable and affordable medical interventions for such diseases, (such as drugs, microbicides or vaccines, including their delivery modality, follow up of treatment and prevention in the affected population as well as medical diagnostics to detect and monitor disease/health evolution.)

    The specific objectives will be, inter alia :

    ·        an increased number of new or improved medical interventions for HIV/AIDS, tuberculosis, malaria and other poverty-related diseases, including neglected ones, and by the end of the programme to have delivered at least one new medical intervention, issued approximately 30 guidelines, and have progressed the clinical development of approximately 20 candidate medical interventions;

    ·        establish the research priorities in an objective-orientated manner in order to accelerate results and contribute to the control and eradication of poverty-related diseases, including neglected ones;

    ·        extend international cooperation with other public and private partners to ensure that the impact of all research is maximised and that synergies can be taken into consideration and achieve leveraging of resources and investments.

    In order to reach the specific objectives, operational indicators and objectives would be monitored during the course of the EDCTP2 programme.

    Agreements between the Union and the EDCTP2-IS : these must set out provisions for the publication of calls for proposals by EDCTP2, in particular on the single portal for participants as well as through other Horizon 2020 electronic means of dissemination managed by the Commission.

    Audits: administrative burdens should be reduced for all parties. Double audits and disproportionate documentation and reporting should be avoided.

    Evaluation: the Commission must carry out, with the assistance of independent experts, an interim evaluation of the EDCTP2 Programme by 30 June 2017 and report to Parliament and Council by 31 December 2017. The results of the independent interim evaluation should be taken into account in the interim evaluation of Horizon 2020.

activities/7
date
2014-05-06T00:00:00
body
CSL
type
Council Meeting
council
Economic and Financial Affairs ECOFIN
meeting_id
3310
activities/8
date
2014-05-06T00:00:00
body
EP/CSL
type
Act adopted by Council after Parliament's 1st reading
procedure/stage_reached
Old
Provisional agreement between Parliament and Council on final act
New
Awaiting signature of act
procedure/stage_reached
Old
Awaiting Council 1st reading position / budgetary conciliation convocation
New
Provisional agreement between Parliament and Council on final act
activities/6/docs
  • type: Decision by Parliament, 1st reading/single reading title: T7-0366/2014
activities/6/type
Old
Vote in plenary scheduled
New
Decision by Parliament, 1st reading/single reading
procedure/stage_reached
Old
Awaiting Parliament 1st reading / single reading / budget 1st stage
New
Awaiting Council 1st reading position / budgetary conciliation convocation
activities/2/docs
  • url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=3258*&MEET_DATE=26/09/2013 type: Debate in Council title: 3258
activities/2/docs
  • url: http://register.consilium.europa.eu/content/out?lang=EN&ff_FT_TEXT=3258&dd_DATE_REUNION=26/09/2013&single_date=26/09/2013 type: Debate in Council title: 3258
activities/5/docs/0/text
  • The Committee on Industry, Research and Energy adopted the report by Vicky FORD (ECR, UK) on the proposal for a decision of the European Parliament and of the Council on the participation of the Union in a second European and Developing Countries Clinical Trials Partnership Programme (EDCTP2) jointly undertaken by several Member States.

    The parliamentary committee recommended that the position adopted by the European Parliament at first reading under the ordinary legislative procedure should amend the Commission’s proposal as follows:

    Union's financial contribution: this shall be EUR 648.85 million (as opposed to EUR 683 million in the Commission proposal) matching the contributions of the participating states. This contribution shall be paid from the appropriations in the general budget of the Union allocated to the relevant parts of the Specific Programme implementing Horizon 2020 Framework Programmeand, in particular, from the appropriations under the specific objective “Health, demographic change and wellbeing”.

    Scope: Members suggested changing and extending the current scope of EDCTP1:

    • further strengthening the capabilities in developing countries for sound conduct and management of clinical trials, in particular, the role and development of ethical review committees and the corresponding regulatory environment, the coordination, collaboration and, where appropriate;
    • extending public-private partnerships (P2Ps) such as the Product Development Partnerships (PDPs), civil society, non-governmental organisations and foundations;
    • making the rules of governance more clear and transparent.

    Activities of the programme EDCTP2: the activities may include activities undertaken by public or private not-for-profit research organisations included in the national programme activities of participating states.

    These activities must also contribute to:

    • supporting clinical trial research and related activities on poverty-related diseases, in particular, HIV/AIDS, malaria, tuberculosis and other poverty related and neglected diseases, devoting special attention to neglected diseases that are already affecting Sub-Saharan Africa and Europe;
    • launching joint actions with industry and product development partnerships, aiming at reinforcing national health systems and facilitating transfers of results to the population concerned;
    • assuring awareness, endorsement and acknowledgment of the EDCTP2 Programme and its activities through advocacy and communication, not only at European Union level and in developing countries, but also at global level.

    Conditions applicable to the Union’s financial contribution: Members stressed the need to ensure that there be a strong coherence between the activities of the P2Ps and the research priorities defined in the Horizon 2020 Framework Programme, such as open access, equality between men and women and non-discrimination.

    Rules for the participation and dissemination of results: an amendment sought to clearly establish that the Rules of Procedure apply and that projects are integrated and selected via competitive calls.

    Members requested that all calls and opportunities to participate be widely advertised, including on the Commission's Horizon 2020 website which shall include a chapter dedicated to EDCTP2.

    Audits: without prejudice to the independence or the role of the Court of Auditors of the European Union, the Commission may, in duly reasoned cases and in consultation with the participating states, decide to carry out ex post audits of indirect activities itself.

    Evaluation: the Commission shall organise an independent interim evaluation of the EDCTP2 Programme by 30 June 2017 and send that report to the European Parliament and to the Council by 31 December 2017. The result of the independent interim evaluation of EDCTP2 shall be taken into account in the interim evaluation of Horizon 2020.

    In order to respond to unforeseen situations or to new developments and needs the Commission may, following the interim evaluation of Horizon 2020, review, within the annual budgetary procedure, the budget of EDCTP2.

activities/6/type
Old
Indicative plenary sitting date, 1st reading/single reading
New
Vote in plenary scheduled
activities/2/docs/0/url
Old
http://www.europarl.europa.eu/ http://register.consilium.europa.eu/servlet/driver?page=Result&typ=Simple&cmsid=638&ff_COTE_DOCUMENT=&ff_TITRE=&ff_SOUS_COTE_MATIERE=&fc=REGAISEN&srm=25&md=400&ssf=DATE_DOCUMENT+DESC&single_comparator=%3D&from_date=&to_date=&lang=EN&ff_FT_TEXT=3258&dd_DATE_REUNION=26/09/2013&single_date=26/09/2013
New
http://register.consilium.europa.eu/content/out?lang=EN&ff_FT_TEXT=3258&dd_DATE_REUNION=26/09/2013&single_date=26/09/2013
activities/5/docs
  • url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2014-0064&language=EN type: Committee report tabled for plenary, 1st reading/single reading title: A7-0064/2014
activities/0/docs/0/celexid
Old
CELEX:52013DC0498(01):EN
New
CELEX:52013PC0498:EN
activities/0/docs/0/celexid
Old
CELEX:52013PC0498:EN
New
CELEX:52013DC0498(01):EN
procedure/Modified legal basis
Rules of Procedure of the European Parliament EP 138
activities/5
date
2014-01-29T00:00:00
body
EP
type
Committee report tabled for plenary, 1st reading/single reading
committees
procedure/stage_reached
Old
Awaiting committee decision
New
Awaiting Parliament 1st reading / single reading / budget 1st stage
activities/4/committees
  • body: EP responsible: False committee_full: Budgets committee: BUDG
  • body: EP responsible: False committee: DEVE date: 2013-11-11T00:00:00 committee_full: Development rapporteur: group: EPP name: PONGA Maurice
  • body: EP responsible: False committee_full: Environment, Public Health and Food Safety committee: ENVI
  • body: EP shadows: group: EPP name: CARVALHO Maria Da Graça group: S&D name: RIERA MADURELL Teresa group: ALDE name: HALL Fiona group: Verts/ALE name: RIVASI Michèle responsible: True committee: ITRE date: 2013-10-14T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: ECR name: FORD Vicky
activities/4/type
Old
Vote scheduled in committee, 1st reading/single reading
New
Vote in committee, 1st reading/single reading
procedure/Modified legal basis
Rules of Procedure of the European Parliament EP 138
activities/0
date
2013-07-10T00:00:00
docs
body
EC
type
Legislative proposal
commission
DG: url: http://ec.europa.eu/research/home.cfm title: Research and Innovation Commissioner: GEOGHEGAN-QUINN Máire
activities/0/body
Old
EP
New
EC
activities/0/commission
  • DG: url: http://ec.europa.eu/research/home.cfm title: Research and Innovation Commissioner: GEOGHEGAN-QUINN Máire
activities/0/date
Old
2013-12-05T00:00:00
New
2013-07-10T00:00:00
activities/0/docs/0/celexid
CELEX:52013PC0498:EN
activities/0/docs/0/text
  • PURPOSE: to enable the participation of the Union in a second European and Developing Countries Clinical Trials Partnership Programme jointly undertaken by several Member States.

    PROPOSED ACT: Decision of the European Parliament and of the Council.

    ROLE OF THE EUROPEAN PARLIAMENT: the European Parliament decides in accordance with the ordinary legislative procedure and on an equal footing with the Council.

    BACKGROUND: the European and Developing Countries Clinical Trials Partnership (EDCTP) was established in 2003 in response to the global health crisis caused by the three main poverty-related diseases - HIV/AIDS, malaria and tuberculosis - and to the EU’s commitment to achieving the United Nation’s Millennium Development Goals by 2015. The first EDCTP programme (EDCTP-I 2003-2012) is now beyond its active funding period.

    EDCTP-I had major achievements and has so far developed eight improved medical treatments, in particular for new-borns, children or pregnant/lactating women suffering from HIV/AIDS or malaria. It has resulted in the launch of the first four African Regional Networks of Excellence promoting South-South cooperation on clinical research and more than 400 African researchers have been trained. It has also contributed to establishing the Pan-African Clinical Trials Registry and the African Vaccine Regulators Forum.

    Despite the results and impact of EDCTP so far, the health and socio-economic burden of poverty-related diseases persists and hinders the sustainable development of developing countries, in particular in sub-Saharan Africa. More than one billion people, including 400 million children, are suffering from one or more poverty-related diseases, including neglected infectious diseases such as sleeping sickness and worm infections. HIV/AIDS alone kills an estimated 2 million people, while malaria and tuberculosis together kill an estimated 2.2 million people annually.

    Following the recommendations from the independent interim evaluation of EDCTP-I, the Belgian EU Council Presidency proposed, in November 2010, the launch of a second EDCTP joint programme (EDCTP-2) with at least ten years duration (2014-2024). On 15 June 2010, the European Parliament adopted a resolution on progress towards achieving the Millennium Development Goals (MDG) in which it ‘asks the Commission, the Member States and developing countries to address MDG 5 (on improving maternal health), MDG 4 (on child mortality) and MDG 6 (on HIV/AIDS, malaria and tuberculosis) in a coherent and holistic way’.

    IMPACT ASSESSMENT: the external interim evaluations of the EDCTP-I and the impact assessment of the future EDCTP-2 programme call for the programme to be continued but with the next programme lasting 10 years and covering a scope that extends to other poverty-related diseases (beyond HIV/AIDS, tuberculosis and malaria) and to all phases of clinical development. The geographical focus should continue to be on sub-Saharan Africa.

    LEGAL BASIS: Articles 185 and Article 188(2) of the Treaty on the Functioning of the European Union (TFEU).

    CONTENT: the proposal for a decision concerns the participation of the Union in a second European and Developing Countries Clinical Trials Partnership Programme (EDCTP-2) jointly undertaken by Belgium, Denmark, Germany, Ireland, Greece, Spain, France, Italy, Luxembourg, the Netherlands, Austria, Portugal, Sweden and the United Kingdom, as well as Switzerland and Norway.

    EDCTP2 shall contribute to the reduction of the social and economic burden of poverty-related diseases in developing countries, in particular in sub-Saharan Africa, by accelerating the clinical development of effective, safe and affordable medical interventions for poverty-related diseases, in partnership with sub-Saharan Africa.

    EDCTP-2 seeks to achieve the following specific objectives:

    • an increased number of new or improved medical interventions for HIV/AIDS, tuberculosis, malaria and other poverty-related diseases, and by the end of the programme to have delivered (i) at least one new medical intervention; (ii) to have issued at least 30 guidelines for improved or extended use of existing medical interventions; and (iii) to have progressed the clinical development of at least 20 candidate medical interventions;
    • strengthened cooperation with sub-Saharan African countries, in particular on building their capacity for conducting clinical trials;
    • better coordination, alignment and integration of relevant national programmes to increase the cost-effectiveness of European public investments;
    • extended international cooperation with other public and private funders;
    • an increased impact due to effective cooperation with relevant European Union initiatives, including its development assistance.

    EDCTP-2 has been conceived to complement the actions implemented under the European Development Funds and the Development Cooperation Instruments, and to respond to the Union’s commitment to the 2012 Rio+20 conference conclusions on developing and achieving internationally agreed Sustainable Development Goals.

    BUDGETARY IMPLICATION: the Union contribution shall be up to EUR 683 million at current prices including EFTA contribution. The envelope is in current prices. The Union contribution shall be made from the ‘Health, demographic change and wellbeing’ challenge, DG Research & Innovation envelope, as part of the implementation of Horizon 2020 – The Framework Programme for Research and Innovation. The maximum amount of Union contribution for administrative costs is up to EUR 41 million.

activities/0/docs/0/title
Old
PE522.974
New
COM(2013)0498
activities/0/docs/0/type
Old
Amendments tabled in committee
New
Legislative proposal published
activities/0/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE522.974
New
http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2013/0498/COM_COM(2013)0498_EN.pdf
activities/0/type
Old
Amendments tabled in committee
New
Legislative proposal published
activities/3
date
2013-11-12T00:00:00
docs
url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE522.973 type: Committee draft report title: PE522.973
body
EP
type
Committee draft report
activities/7/date
Old
2014-03-12T00:00:00
New
2014-04-15T00:00:00
activities/6
date
2014-01-23T00:00:00
body
EP
type
Vote scheduled in committee, 1st reading/single reading
activities/5/docs/0/url
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE522.974
activities/0/docs/0/celexid
CELEX:52013PC0498:EN
activities/0/docs/0/celexid
CELEX:52013PC0498:EN
activities/4
date
2013-12-03T00:00:00
body
CSL
type
Council Meeting
council
Competitiveness (Internal Market, Industry, Research and Space)
meeting_id
3276
activities/5
date
2013-12-05T00:00:00
docs
type: Amendments tabled in committee title: PE522.974
body
EP
type
Amendments tabled in committee
other/0
body
CSL
type
Council Meeting
council
Former Council configuration
activities/3/docs/0/url
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE522.973
activities/1/committees/1/date
2013-11-11T00:00:00
activities/1/committees/1/rapporteur
  • group: EPP name: PONGA Maurice
activities/3
date
2013-11-12T00:00:00
docs
type: Committee draft report title: PE522.973
body
EP
type
Committee draft report
committees/1/date
2013-11-11T00:00:00
committees/1/rapporteur
  • group: EPP name: PONGA Maurice
activities/3/date
Old
2014-02-25T00:00:00
New
2014-03-12T00:00:00
activities/1/committees/3/date
2013-10-14T00:00:00
activities/1/committees/3/rapporteur
  • group: ECR name: FORD Vicky
activities/1/committees/3/shadows/3
group
Verts/ALE
name
RIVASI Michèle
committees/3/date
2013-10-14T00:00:00
committees/3/rapporteur
  • group: ECR name: FORD Vicky
committees/3/shadows/3
group
Verts/ALE
name
RIVASI Michèle
activities/1/committees/3/shadows/0
group
EPP
name
CARVALHO Maria Da Graça
committees/3/shadows/0
group
EPP
name
CARVALHO Maria Da Graça
activities/1/committees/3/shadows
  • group: S&D name: RIERA MADURELL Teresa
  • group: ALDE name: HALL Fiona
committees/3/shadows
  • group: S&D name: RIERA MADURELL Teresa
  • group: ALDE name: HALL Fiona
activities/2
body
CSL
meeting_id
3258
docs
url: http://www.europarl.europa.eu/ http://register.consilium.europa.eu/servlet/driver?page=Result&typ=Simple&cmsid=638&ff_COTE_DOCUMENT=&ff_TITRE=&ff_SOUS_COTE_MATIERE=&fc=REGAISEN&srm=25&md=400&ssf=DATE_DOCUMENT+DESC&single_comparator=%3D&from_date=&to_date=&lang=EN&ff_FT_TEXT=3258&dd_DATE_REUNION=26/09/2013&single_date=26/09/2013 type: Debate in Council title: 3258
council
Competitiveness (Internal Market, Industry, Research and Space)
date
2013-09-26T00:00:00
type
Council Meeting
activities/0/commission/0
DG
Commissioner
GEOGHEGAN-QUINN Máire
activities/1
date
2013-09-10T00:00:00
body
EP
type
Committee referral announced in Parliament, 1st reading/single reading
committees
activities/2
date
2014-02-25T00:00:00
body
EP
type
Indicative plenary sitting date, 1st reading/single reading
committees/1
body
EP
responsible
False
committee_full
Budgetary Control
committee
CONT
other/0
body
EC
dg
commissioner
GEOGHEGAN-QUINN Máire
procedure/Mandatory consultation of other institutions
Economic and Social Committee
procedure/dossier_of_the_committee
ITRE/7/13414
procedure/stage_reached
Old
Preparatory phase in Parliament
New
Awaiting committee decision
activities/0/docs/0/text
  • PURPOSE: to enable the participation of the Union in a second European and Developing Countries Clinical Trials Partnership Programme jointly undertaken by several Member States.

    PROPOSED ACT: Decision of the European Parliament and of the Council.

    ROLE OF THE EUROPEAN PARLIAMENT: the European Parliament decides in accordance with the ordinary legislative procedure and on an equal footing with the Council.

    BACKGROUND: the European and Developing Countries Clinical Trials Partnership (EDCTP) was established in 2003 in response to the global health crisis caused by the three main poverty-related diseases - HIV/AIDS, malaria and tuberculosis - and to the EU’s commitment to achieving the United Nation’s Millennium Development Goals by 2015. The first EDCTP programme (EDCTP-I 2003-2012) is now beyond its active funding period.

    EDCTP-I had major achievements and has so far developed eight improved medical treatments, in particular for new-borns, children or pregnant/lactating women suffering from HIV/AIDS or malaria. It has resulted in the launch of the first four African Regional Networks of Excellence promoting South-South cooperation on clinical research and more than 400 African researchers have been trained. It has also contributed to establishing the Pan-African Clinical Trials Registry and the African Vaccine Regulators Forum.

    Despite the results and impact of EDCTP so far, the health and socio-economic burden of poverty-related diseases persists and hinders the sustainable development of developing countries, in particular in sub-Saharan Africa. More than one billion people, including 400 million children, are suffering from one or more poverty-related diseases, including neglected infectious diseases such as sleeping sickness and worm infections. HIV/AIDS alone kills an estimated 2 million people, while malaria and tuberculosis together kill an estimated 2.2 million people annually.

    Following the recommendations from the independent interim evaluation of EDCTP-I, the Belgian EU Council Presidency proposed, in November 2010, the launch of a second EDCTP joint programme (EDCTP-2) with at least ten years duration (2014-2024). On 15 June 2010, the European Parliament adopted a resolution on progress towards achieving the Millennium Development Goals (MDG) in which it ‘asks the Commission, the Member States and developing countries to address MDG 5 (on improving maternal health), MDG 4 (on child mortality) and MDG 6 (on HIV/AIDS, malaria and tuberculosis) in a coherent and holistic way’.

    IMPACT ASSESSMENT: the external interim evaluations of the EDCTP-I and the impact assessment of the future EDCTP-2 programme call for the programme to be continued but with the next programme lasting 10 years and covering a scope that extends to other poverty-related diseases (beyond HIV/AIDS, tuberculosis and malaria) and to all phases of clinical development. The geographical focus should continue to be on sub-Saharan Africa.

    LEGAL BASIS: Articles 185 and Article 188(2) of the Treaty on the Functioning of the European Union (TFEU).

    CONTENT: the proposal for a decision concerns the participation of the Union in a second European and Developing Countries Clinical Trials Partnership Programme (EDCTP-2) jointly undertaken by Belgium, Denmark, Germany, Ireland, Greece, Spain, France, Italy, Luxembourg, the Netherlands, Austria, Portugal, Sweden and the United Kingdom, as well as Switzerland and Norway.

    EDCTP2 shall contribute to the reduction of the social and economic burden of poverty-related diseases in developing countries, in particular in sub-Saharan Africa, by accelerating the clinical development of effective, safe and affordable medical interventions for poverty-related diseases, in partnership with sub-Saharan Africa.

    EDCTP-2 seeks to achieve the following specific objectives:

    • an increased number of new or improved medical interventions for HIV/AIDS, tuberculosis, malaria and other poverty-related diseases, and by the end of the programme to have delivered (i) at least one new medical intervention; (ii) to have issued at least 30 guidelines for improved or extended use of existing medical interventions; and (iii) to have progressed the clinical development of at least 20 candidate medical interventions;
    • strengthened cooperation with sub-Saharan African countries, in particular on building their capacity for conducting clinical trials;
    • better coordination, alignment and integration of relevant national programmes to increase the cost-effectiveness of European public investments;
    • extended international cooperation with other public and private funders;
    • an increased impact due to effective cooperation with relevant European Union initiatives, including its development assistance.

    EDCTP-2 has been conceived to complement the actions implemented under the European Development Funds and the Development Cooperation Instruments, and to respond to the Union’s commitment to the 2012 Rio+20 conference conclusions on developing and achieving internationally agreed Sustainable Development Goals.

    BUDGETARY IMPLICATION: the Union contribution shall be up to EUR 683 million at current prices including EFTA contribution. The envelope is in current prices. The Union contribution shall be made from the ‘Health, demographic change and wellbeing’ challenge, DG Research & Innovation envelope, as part of the implementation of Horizon 2020 – The Framework Programme for Research and Innovation. The maximum amount of Union contribution for administrative costs is up to EUR 41 million.

activities
  • date: 2013-07-10T00:00:00 docs: url: http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2013/0498/COM_COM(2013)0498_EN.pdf title: COM(2013)0498 type: Legislative proposal published celexid: CELEX:52013PC0498:EN url: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=SWD:2013:0253:FIN:EN:PDF type: Document attached to the procedure title: SWD(2013)0253 url: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=SWD:2013:0254:FIN:EN:PDF type: Document attached to the procedure title: SWD(2013)0254 type: Legislative proposal body: EC commission:
committees
  • body: EP responsible: False committee_full: Budgets committee: BUDG
  • body: EP responsible: False committee_full: Budgetary Control committee: CONT
  • body: EP responsible: False committee_full: Development committee: DEVE
  • body: EP responsible: False committee_full: Environment, Public Health and Food Safety committee: ENVI
  • body: EP responsible: True committee_full: Industry, Research and Energy committee: ITRE
links
National parliaments
European Commission
other
    procedure
    reference
    2013/0243(COD)
    instrument
    Decision
    legal_basis
    stage_reached
    Preparatory phase in Parliament
    summary
    See also
    subtype
    Legislation
    title
    Second European and Developing Countries Clinical Trials Partnership Programme: participation of the Union
    type
    COD - Ordinary legislative procedure (ex-codecision procedure)
    subject